ICON plc (ICLR)

155.47
0.10 0.06
NASDAQ : Health Technology
Prev Close 155.57
Open 156.01
Day Low/High 154.50 / 156.68
52 Wk Low/High 118.10 / 165.13
Volume 18.41K
Avg Volume 234.20K
Exchange NASDAQ
Shares Outstanding 54.08M
Market Cap 8.48B
EPS 6.00
P/E Ratio 26.61
Div & Yield N.A. (N.A)
ICON Reports Second Quarter 2013 Revenue Of $334 Million, Up 21% Year On Year, Non-GAAP EPS Of 43c And Raises FY 2013 Guidance.

ICON Reports Second Quarter 2013 Revenue Of $334 Million, Up 21% Year On Year, Non-GAAP EPS Of 43c And Raises FY 2013 Guidance.

ICON plc, (NASDAQ: ICLR), a global provider of outsourced development services to the pharmaceutical, biotechnology and medical device industries, today reported its financial results for the second quarter...

ICON Shareholders Vote In Favour Of All Resolutions At Its Annual General Meeting

ICON Shareholders Vote In Favour Of All Resolutions At Its Annual General Meeting

ICON plc , (NASDAQ: ICLR), a global provider of outsourced development services to the pharmaceutical, biotechnology and medical device industries, today announced that all resolutions at the Annual General...

The Great Crabtree Technology Portfolio Rebalancing Act

The Great Crabtree Technology Portfolio Rebalancing Act

Here's the latest quarterly reshuffle of our portfolio holdings.

4 Stocks Rising on Unusual Volume

4 Stocks Rising on Unusual Volume

Unusual volume can be a major signal that hedge funds and momentum traders are piling into a stock ahead of a catalyst.

ICON Announces Appointment Of Professor William Hall To Board Of Directors

ICON Announces Appointment Of Professor William Hall To Board Of Directors

ICON plc, (NASDAQ: ICLR), a global provider of outsourced development services to the pharmaceutical, biotechnology and medical device industries, today announced the appointment of Professor William Hall as a...

ICON Reports Fourth Quarter 2012 Revenue Of $300 Million, Up 24% Year On Year, EPS Of 34c And Full Year Revenue Of $1.12 Billion, EPS Of $1.00.

ICON Reports Fourth Quarter 2012 Revenue Of $300 Million, Up 24% Year On Year, EPS Of 34c And Full Year Revenue Of $1.12 Billion, EPS Of $1.00.

ICON plc, (NASDAQ: ICLR), a global provider of outsourced development services to the pharmaceutical, biotechnology and medical device industries, today reported its financial results for the full year and...

Cross Country Healthcare Completes Sale Of Its Clinical Trial Services Business

Cross Country Healthcare Completes Sale Of Its Clinical Trial Services Business

Cross Country Healthcare, Inc. (Nasdaq: CCRN) announced today it has completed the previously announced sale of its clinical trial services business to ICON plc (NASDAQ: ICLR) for $52 million, plus an earn-out of up to...

ICON Announces The Commencement Of Direct Trading On NASDAQ

ICON Announces The Commencement Of Direct Trading On NASDAQ

ICON plc , (NASDAQ: ICLR) (ISIN:IE0005711209), a global provider of outsourced development services to the pharmaceutical, biotechnology and medical device industries, commenced direct trading of ICON ordinary...

Mr. Thomas Lynch Elected As Chairman Of ICON Plc

Mr. Thomas Lynch Elected As Chairman Of ICON Plc

ICON plc, (NASDAQ: ICLR)(ISIN: IE0005711209), a global provider of outsourced development services to the pharmaceutical, biotechnology and medical device industries, today announced that, Mr.

ICON Shareholders Vote In Favour Of All Resolutions At Its Extraordinary General Meeting Relating To The Proposed Conversion To A Direct Listing Of ICON’s Shares On NASDAQ

ICON Shareholders Vote In Favour Of All Resolutions At Its Extraordinary General Meeting Relating To The Proposed Conversion To A Direct Listing Of ICON’s Shares On NASDAQ

ICON plc , (NASDAQ:ICLR) (ISIN:IE0005711209), a global provider of outsourced development services to the pharmaceutical, biotechnology and medical device industries, today announced that all resolutions ...

ICON Plc Provides 2013 Financial Guidance Ahead Of Investor Day In New York

ICON Plc Provides 2013 Financial Guidance Ahead Of Investor Day In New York

ICON plc. (NASDAQ:ICLR) (ISIN:IE0005711209), a global provider of outsourced development services to the pharmaceutical, biotechnology and medical device industries, is hosting an Investor Day in New York ...

Dr. Bruce Given Notifies ICON That He Will Not Seek A Further Term As Chairman Of The Board

Dr. Bruce Given Notifies ICON That He Will Not Seek A Further Term As Chairman Of The Board

ICON plc . (NASDAQ:ICLR) (ISIN:IE0005711209), a global provider of outsourced development services to the pharmaceutical, biotechnology and medical device industries, today announced that Dr.

Icon PLC Stock Upgraded (ICLR)

Icon PLC Stock Upgraded (ICLR)

Icon (Nasdaq:ICLR) has been upgraded by TheStreet Ratings from a hold to buy.

ICON Announces Publication Of EGM Circular In Respect Of Proposed Conversion To Direct Listing Of Its Shares On NASDAQ

ICON Announces Publication Of EGM Circular In Respect Of Proposed Conversion To Direct Listing Of Its Shares On NASDAQ

ICON plc , (NASDAQ: ICLR) (ISIN:IE0005711209), a global provider of outsourced development services to the pharmaceutical, biotechnology and medical device industries, today announced the publication and filing...

ICON Launches New Functional Service Provision (FSP) Strategy

ICON Launches New Functional Service Provision (FSP) Strategy

ICON plc, (NASDAQ: ICLR; ISIN: IE0005711209), a global provider of outsourced development services to the pharmaceutical, biotechnology and medical device industries, today announced a new functional resourcing...

Icon PLC Stock Downgraded (ICLR)

Icon PLC Stock Downgraded (ICLR)

Icon (Nasdaq:ICLR) has been downgraded by TheStreet Ratings from from a buy to hold.

4 Stocks Rising With Big Volume

4 Stocks Rising With Big Volume

Often when above-average volume moves into an equity, it precedes a large spike in volatility.

ICON Reports Q3 Revenue Of $286 Million, EPS Of 29c And Net New Business Of $450 Million. (NASDAQ: ICLR) (ISIN:IE0005711209)

ICON Reports Q3 Revenue Of $286 Million, EPS Of 29c And Net New Business Of $450 Million. (NASDAQ: ICLR) (ISIN:IE0005711209)

ICON (NASDAQ:ICLR) (ISIN:IE0005711209) , a global provider of outsourced development services to the pharmaceutical, biotechnology and medical device industries, today reported its financial results for the third ...

8 Stocks Spiking on Unusual Volume

8 Stocks Spiking on Unusual Volume

Unusual volume can be a major signal that hedge funds and momentum traders are piling into a stock ahead of a catalyst.

ICON Reports A 10% Increase In First Quarter 2012 Revenue To $252m, Up 10% Year On Year, EPS Of 15 Cents, Net New Business Awards Of $385 Million And A B:B Of 1.5. (NASDAQ:ICLR) (ISIN:IE0005711209)

ICON Reports A 10% Increase In First Quarter 2012 Revenue To $252m, Up 10% Year On Year, EPS Of 15 Cents, Net New Business Awards Of $385 Million And A B:B Of 1.5. (NASDAQ:ICLR) (ISIN:IE0005711209)

ICON (NASDAQ: ICLR) (ISIN:IE0005711209), a global provider of outsourced development services to the pharmaceutical, biotechnology and medical device industries, today reported its financial results for the first...

ICON Selected By Roche For Technology Partnership

ICON Selected By Roche For Technology Partnership

ICON plc, (NASDAQ: ICLR; ISIN:IE0005711209), a global provider of outsourced development services to the pharmaceutical, biotechnology and medical device industries, today announced that it has been selected by Roche...

ICON Acquires PriceSpective

ICON Acquires PriceSpective

ICON plc, (NASDAQ:ICLR) (ISIN:IE0005711209), a global provider of outsourced development services to the pharmaceutical, biotechnology and medical device industries, today announced the acquisition of PriceSpective...

ICON Reports Fourth Quarter 2011 Revenue Of $243m, Up 5% Year On Year, And EPS Of $0.07. Backlog Increases 19%. (NASDAQ:ICLR) (ISIN:IE0005711209)

ICON Reports Fourth Quarter 2011 Revenue Of $243m, Up 5% Year On Year, And EPS Of $0.07. Backlog Increases 19%. (NASDAQ:ICLR) (ISIN:IE0005711209)

ICON (NASDAQ:ICLR) (ISIN:IE0005711209), a global provider of outsourced development services to the pharmaceutical, biotechnology and medical device industries, today reported its financial results for the full year...

10 Top Morningstar M&A Stock Picks for 2012

10 Top Morningstar M&A Stock Picks for 2012

Morningstar's 10 best investment ideas among potential M&A candidates.

ICON Selected By Shire Plc’s Specialty Pharmaceuticals Division As Global Strategic Partner For Clinical Research And Central Laboratory Services

ICON Selected By Shire Plc’s Specialty Pharmaceuticals Division As Global Strategic Partner For Clinical Research And Central Laboratory Services

ICON plc, (NASDAQ: ICLR; ISIN:IE0005711209), a global provider of outsourced development services to the pharmaceutical, biotechnology and medical device industries, today announced that is has signed a strategic...

ICON Announces Dr. Anthony Murphy To Retire From Board Of Directors

ICON Announces Dr. Anthony Murphy To Retire From Board Of Directors

ICON plc., (NASDAQ:ICLR)(ISIN:IE0005711209), a global provider of outsourced development services to the pharmaceutical, biotechnology and medical device industries, today announced the retirement of Non-Executive...

ICON Acquires BeijingWits Medical Consulting Ltd

ICON Acquires BeijingWits Medical Consulting Ltd

ICON plc, (NASDAQ: ICLR; ISIN: IE0005711209), a global provider of outsourced development services to the pharmaceutical, biotechnology and medical device industries, today announced that it has agreed, subject to...

Tasly Pharmaceuticals Selects ICON As It Seeks First FDA Approval Of A Traditional Chinese Medicine

Tasly Pharmaceuticals Selects ICON As It Seeks First FDA Approval Of A Traditional Chinese Medicine

ICON plc, (NASDAQ: ICLR; ISIN:IE0005711209), a global provider of outsourced development services to the pharmaceutical, biotechnology and medical device industries, today announced that it has been selected by Tasly...

ICON Reports Q3 Revenue Growth Of 7% To $241 Million And Net New Business Of $431 Million. (NASDAQ:ICLR) (ISIN:IE0005711209)

ICON Reports Q3 Revenue Growth Of 7% To $241 Million And Net New Business Of $431 Million. (NASDAQ:ICLR) (ISIN:IE0005711209)

ICON (NASDAQ:ICLR)(ISIN:IE0005711209), a global provider of outsourced development services to the pharmaceutical, biotechnology and medical device industries, today reported its financial results for the third...

A Bit of Green for These Irish Plays

Ireland is not dissolving into the sea, contrary to popular belief -- and these are two strong Irish companies that should continue performing well.

TheStreet Quant Rating: A (Buy)